The QWINT-3 study compared efsitora with daily shots of Novo Nordisk’s NVO Tresiba (insulin degludec) for 78 weeks in T2D patients who have switched from daily basal insulin injections.

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

For many patients with type 2 diabetes, having to inject basal insulin every day ... as daily dosing with Novo Nordisk's Tresiba (insulin degludec) once per day at controlling blood glucose ...

The company is conducting five registrational QWINT studies to establish that once-weekly efsitora is not inferior to daily insulin injection ... glargine and insulin degludec, respectively.

After decades of optimizations to develop longer-acting insulin preparations to reduce the number of daily injections ... including long-acting insulin degludec, rapid-acting insulin aspart ...

This leaflet answers some common questions about Ryzodeg ® 70/30 FlexTouch ®. It does not contain all the available information. It does not take the place of talking to your doctor, diabetes ...